Genetic Technologies ( NASDAQ: GENE ) announces the start of testing operations in the United States for its revolutionary geneType genetic risk assessment product series. GeneType’s multi-patented, clinically validated tests will now be performed by Gene by Gene. Gene by Gene’s ability to process up to 25,000 tests per month greatly increases geneType’s operational capacity in North America.
Source: Press Release More on Genetic Technologies Genetic Technologies stock tumbles on direct offering pricing Financial information for Genetic Technologies.
